Memory Pharmaceuticals Corp. geht ab - Rebound!!! - 500 Beiträge pro Seite

[Fittibaldi]

Gestern legte Memory Pharma 16,97% an der Nasdaq NM zu,
ich denke das es in den nächsten Tagen noch weiter nach
oben geht.
Memory Pharma stand im März noch bei 5 USD!!!

Hier eine Übersicht der Insiderkäufe!!!
Insider purchase (P) or sell (S): Code Transaction
Date Reported
Date Company Symbol Insider Relationship Shares Average
Unit Price Total
Amount Shares
Owned Filing
P 2005-09-23 2005-09-27 19:23:46 MEMORY PHARMACEUTICALS CORP MEMY MARDUEL ALIX No longer a Director 789,474 $0 $0.00 1.73418e+06 View
P 2005-09-23 2005-09-26 17:51:18 MEMORY PHARMACEUTICALS CORP MEMY EVNIN ANTHONY B Director 973,684 $1.9 $1,849,999.60 1.21319e+06 View
P 2005-09-23 2005-09-23 18:17:46 MEMORY PHARMACEUTICALS CORP MEMY WALTON ALAN G 10% owner 3.1579e+06 $1.9 $6,000,000.50 2.60544e+06 View
P 2005-09-23 2005-09-23 18:08:54 MEMORY PHARMACEUTICALS CORP MEMY SULAT JAMES R President & CEO
Director 157,895 $1.9 $300,000.50 157,895 View
P 2005-09-23 2005-09-23 18:07:21 MEMORY PHARMACEUTICALS CORP MEMY SCULLION TONY President & CEO
Director 39,474 $1.9 $75,000.60 178,030 View
P 2005-09-23 2005-09-23 18:06:40 MEMORY PHARMACEUTICALS CORP MEMY MEYERS MICHAEL E Director 26,316 $1.9 $50,000.40 26,316 View
P 2005-09-23 2005-09-23 18:06:06 MEMORY PHARMACEUTICALS CORP MEMY Lowe David A Chief Scientific Officer
Director 26,316 $1.9 $50,000.40 26,316 View
P 2005-09-23 2005-09-23 18:05:37 MEMORY PHARMACEUTICALS CORP MEMY KRIEBEL ROBERT I Director 5,000 $1.9 $9,500.00 5,000 View
P 2005-09-23 2005-09-23 18:04:52 MEMORY PHARMACEUTICALS CORP MEMY GILBERT WALTER PHD Director 52,632 $1.9 $100,000.80 185,964 View

Derivative transactions (such as stock option award, conversion, exercise, etc): Code Title Transaction
Date Exercisable
Date Reported
Date Company Symbol Insider Relationship Shares Conversion
Price Shares
Owned Filing
P Warrant (Right to Buy) 2005-09-23 N/A 2005-09-27 19:23:46 MEMORY PHARMACEUTICALS CORP MEMY MARDUEL ALIX No longer a Director 276,315 $0.00 276,315 View
P Warrant (Right to Buy) 2005-09-23 2006-03-22 2005-09-26 17:51:18 MEMORY PHARMACEUTICALS CORP MEMY EVNIN ANTHONY B Director 64,473 $2.22 64,473 View
P Warrant (Right to Buy) 2005-09-23 2006-03-22 2005-09-26 17:51:18 MEMORY PHARMACEUTICALS CORP MEMY EVNIN ANTHONY B Director 113,289 $2.22 113,289 View
P Warrant (Right to Buy) 2005-09-23 2006-03-22 2005-09-26 17:51:18 MEMORY PHARMACEUTICALS CORP MEMY EVNIN ANTHONY B Director 163,026 $2.22 163,026 View
P Warrant (right to buy) 2005-09-23 2006-03-22 2005-09-23 18:17:46 MEMORY PHARMACEUTICALS CORP MEMY WALTON ALAN G 10% owner 184,210 $2.22 184,210 View
P Warrant (right to buy) 2005-09-23 2006-03-22 2005-09-23 18:17:46 MEMORY PHARMACEUTICALS CORP MEMY WALTON ALAN G 10% owner 911,902 $2.22 911,902 View
P Warrant (right to buy) 2005-09-23 2006-03-22 2005-09-23 18:17:46 MEMORY PHARMACEUTICALS CORP MEMY WALTON ALAN G 10% owner 9,149 $2.22 9,149 View
P Common Stock Warrant (right to buy) 2005-09-23 2006-03-22 2005-09-23 18:08:54 MEMORY PHARMACEUTICALS CORP MEMY SULAT JAMES R President & CEO
Director 55,263 $2.22 55,263 View
P Common Stock Warrant (right to buy) 2005-09-23 2006-03-22 2005-09-23 18:07:21 MEMORY PHARMACEUTICALS CORP MEMY SCULLION TONY President & CEO
Director 13,815 $2.22 13,815 View
P Common Stock Warrant (right to buy) 2005-09-23 2006-03-22 2005-09-23 18:06:40 MEMORY PHARMACEUTICALS CORP MEMY MEYERS MICHAEL E Director 9,210 $2.22 9,210 View
P Common Stock Warrant (right to buy) 2005-09-23 2006-03-22 2005-09-23 18:06:06 MEMORY PHARMACEUTICALS CORP MEMY Lowe David A Chief Scientific Officer
Director 9,210 $2.22 9,210 View
P Common Stock Warrant (right to buy) 2005-09-23 2006-03-22 2005-09-23 18:05:37 MEMORY PHARMACEUTICALS CORP MEMY KRIEBEL ROBERT I Director 1,750 $2.22 1,750 View
P Common Stock Warrant (right to buy) 2005-09-23 2006-03-22 2005-09-23 18:04:52 MEMORY PHARMACEUTICALS CORP MEMY GILBERT WALTER PHD Director 18,421 $2.22 18,421 View
A Employee Stock Option (Right to Buy) 2005-08-15 2005-08-15 2005-08-16 16:17:54 MEMORY PHARMACEUTICALS CORP MEMY SULAT JAMES R President & CEO
Director 525,000 $2.24 525,000 View
A Stock Option (Right to Buy) 2005-07-28 2006-07-28 2005-08-01 15:09:20 MEMORY PHARMACEUTICALS CORP MEMY EVNIN ANTHONY B Director 10,000 $2.25 10,000 View
A Stock Option (Right to Buy) 2005-07-28 2006-07-28 2005-07-29 16:00:15 MEMORY PHARMACEUTICALS CORP MEMY FLEMING JONATHAN Director 10,000 $2.25 10,000 View
A Stock Option (Right to Buy) 2005-07-28 2006-07-28 2005-07-29 13:10:02 MEMORY PHARMACEUTICALS CORP MEMY GILBERT WALTER PHD Director 10,000 $2.25 10,000 View
A Stock Option (Right to Buy) 2005-07-28 2006-07-28 2005-07-28 18:52:59 MEMORY PHARMACEUTICALS CORP MEMY MEYERS MICHAEL E Director 10,000 $2.25 10,000 View
A Stock Option (Right to Buy) 2005-07-28 2006-07-28 2005-07-28 17:19:39 MEMORY PHARMACEUTICALS CORP MEMY KRIEBEL ROBERT I Director 10,000 $2.25 10,000 View
A Stock Option (Right to Buy) 2005-07-28 2006-07-28 2005-07-28 17:18:41 MEMORY PHARMACEUTICALS CORP MEMY MEYERS MICHAEL E Director 10,000 $2.25 10,000 View
A Stock Option (Right to Buy) 2005-07-28 2006-07-28 2005-07-28 17:17:46 MEMORY PHARMACEUTICALS CORP MEMY Young Peter Director 10,000 $2.25 10,000 View
A Employee Stock Option (Right to Buy) 2005-05-17 2005-05-17 2005-05-18 16:36:20 MEMORY PHARMACEUTICALS CORP MEMY SULAT JAMES R President & CEO
Director 500,000 $2.45 500,000 View
A Employee Stock Option (Right to Buy) 2005-05-12 2005-05-12 2005-05-16 17:34:22 MEMORY PHARMACEUTICALS CORP MEMY Lalani Jzaneen VP Legal Affairs 35,000 $2.39 35,000 View
A Employee Stock Option (right to buy) 2005-05-12 2005-05-12 2005-05-16 17:28:15 MEMORY PHARMACEUTICALS CORP MEMY SMITH GARDINER F H Chief Business Officer 45,000 $2.39 45,000 View
A Stock Option (Right to Buy) 2005-05-12 2005-05-12 2005-05-16 17:27:34 MEMORY PHARMACEUTICALS CORP MEMY Lowe David A Chief Scientific Officer
Director 55,000 $2.39 55,000 View
A Employee Stock Option (Right to Buy) 2005-05-12 2005-05-12 2005-05-16 17:22:21 MEMORY PHARMACEUTICALS CORP MEMY Donabauer Joseph M Vice President & Controller 30,000 $2.39 30,000 View
M Employee Stock Option (Right to Buy) 2005-04-29 2001-09-04 2005-05-02 17:53:15 MEMORY PHARMACEUTICALS CORP MEMY SCULLION TONY President & CEO
Director 35,000 $0.75 260,242 View

[Fittibaldi]

Heute wieder + 20% !!!

[panik]

Memory Pharmaceuticals Announces Preliminary Results from Safety and Tolerability Study for MEM 1003 in Alzheimer`s Patients
Tuesday December 20, 6:00 am ET
- MEM 1003 Safe and Generally Well Tolerated -
- Company to Host Conference Call Today at 9:00 a.m. EST -


MONTVALE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced preliminary results from its Phase 1b U.S. safety and tolerability study of MEM 1003 in Alzheimer`s disease patients. In this study, MEM 1003 was safe and generally well-tolerated at the dose ranges tested. In addition, the results demonstrated that MEM 1003 is cognitively safe in patients with Alzheimer`s disease.
ADVERTISEMENT


"We were pleased to have achieved the main objective of this study, which confirmed our expectations of the safety profile of MEM 1003. Together with previous clinical and preclinical data, our findings provide a solid rationale for continued development of MEM 1003 as a potential treatment for Alzheimer`s disease," stated David A. Lowe, Ph.D., Chief Scientific Officer. "We are committed to advancing this program, and the objective of our ongoing Phase 2a clinical trial of MEM 1003 is to evaluate the efficacy of this drug candidate in Alzheimer`s disease."

The safety and tolerability study was conducted under a U.S. Investigational New Drug Application. The study consisted of two segments, a double-blind dose escalation segment and a double-blind multiple dose treatment segment. In the first segment of the study MEM 1003 or placebo was administered to 49 patients two times on one day. Patients in this segment of the study were treated at escalating doses of MEM 1003 that reached 120 milligrams per dose two times per day. In the double-blind multiple dose treatment segment, 32 patients received 120 milligrams of MEM 1003 or placebo twice daily for a period of ten days. Vital signs such as heart rate, diastolic and systolic blood pressure both supine and standing were measured at various times during each segment of the study. During the second segment, cognitive function was measured using the Cognitive Drug Research (CDR) battery and the Alzheimer`s Disease Assessment Scale -- cognitive subscale (ADAS-cog).

MEM 1003 was safe and generally well tolerated up to and including a dose of 120 milligrams two times per day by the patients in the double-blind dose escalation segment of this study. MEM 1003 was also safe and generally well tolerated by the patients in the double-blind, multiple dose, 10-day treatment segment. Headache was the most commonly reported adverse event overall. There were no obvious trends in clinical laboratory safety tests, vital signs or electrocardiogram parameters following treatment with MEM 1003. The results also indicated that 10 days of exposure to MEM 1003 did not result in a statistically significant increase or decrease in cognition. On the basis of the safe profile demonstrated in this safety and tolerability study, Memory Pharmaceuticals initiated a Phase 2a study with MEM 1003 in Alzheimer`s disease in November 2005.

MEM 1003 is a neuronal L-type calcium channel modulator that may have applications in Alzheimer`s disease and other diseases associated with cognitive impairment. By blocking L-type calcium channels, MEM 1003 may regulate the flow of calcium and reestablish normal levels of calcium, thereby enhancing cognition and reducing the progression of Alzheimer`s disease.

Conference Call & Webcast

Memory Pharmaceuticals will hold a conference call today at 9:00 a.m. EST to discuss the top-line results from the Phase 1b safety and tolerability study of MEM 1003 in Alzheimer`s disease. The conference call will also be broadcast live from the "Investors" section of the Company`s website. Jim Sulat, President and Chief Executive Officer, and Dr. David Lowe, Chief Scientific Officer, will host the conference call.


Investors and other interested parties may access the call as follows:

Date: Tuesday, December 20, 2005
Time: 9:00 a.m. EST
Telephone (U.S.): 800-638-5495
Telephone (international): 617-614-3946
Participant Passcode: 10758595
Webcast: http://www.memorypharma.com under the
"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EST on Tuesday, December 20, 2005, until Tuesday, December 27, 2005. To access the replay, please dial 888-286-8010 (U.S.) or 617-801-6888 (international) and enter passcode number 31705394. An audio replay of the conference call will also be available under the "Investors" section of the Company`s website during the same period.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer`s disease, schizophrenia, depression, vascular dementia, mild cognitive impairment, Parkinson`s disease and memory impairments associated with aging. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management`s expectations, beliefs, goals, plans or Memory Pharmaceuticals` prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the risks and uncertainties associated with: Memory Pharmaceuticals` ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals` dependence on its collaborations and its license relationship with Bayer; conducting preclinical and clinical trials of Memory Pharmaceuticals` drug candidates that demonstrate these candidates` safety and effectiveness; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals` drug candidates; achieving milestones under Memory Pharmaceuticals` collaborations; obtaining additional financing to support Memory Pharmaceuticals` R&D and clinical activities and operations; Memory Pharmaceuticals` dependence on third- party preclinical or clinical research organizations, manufacturers and consultants; and protecting the intellectual property developed by or licensed to Memory Pharmaceuticals. These and other risks are described in greater detail in Memory Pharmaceuticals` filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.




--------------------------------------------------------------------------------
Source: Memory Pharmaceuticals Corp.

[panik]

Memory Pharmaceuticals Announces Agreement with the Stanley Medical Research Institute for the Development of MEM 1003 for Bipolar Disorder
Tuesday December 20, 6:05 am ET
- Agreement Provides Funding Support for Phase 2a Trial -
- Company to Host Conference Call Today at 9:00 a.m. EST -


MONTVALE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced that it has entered into an agreement with The Stanley Medical Research Institute (SMRI) to develop MEM 1003, the Company`s neuronal L-type calcium channel modulator, as a treatment for bipolar disorder. Under the terms of the agreement, Memory Pharmaceuticals is eligible to receive up to $3.2 million from SMRI to fund the clinical development of MEM 1003 and will use these funds to support a Phase 2a trial of MEM 1003 in acute mania in bipolar disorder, which is scheduled to commence in the first half of 2006. Memory Pharmaceuticals also is currently conducting a Phase 2a clinical trial of MEM 1003 in Alzheimer`s disease.
ADVERTISEMENT


As part of the agreement, SMRI has purchased 440,367 newly issued shares of the Company`s common stock, at a price of $2.18 per share, constituting $960,000 of the total funding being provided to the Company under the agreement. In addition, SMRI received a five-year warrant for the purchase of up to 154,128 additional shares of common stock at an exercise price of $2.62 per share. The Company will receive the remaining $2.24 million of funding upon the achievement of milestones related to the Phase 2a trial in bipolar disorder. These funds will be repayable to SMRI in the form of royalties, up to a specified maximum amount, on future sales of MEM 1003 for the treatment of bipolar disorder or schizophrenia.

"Abnormal calcium levels are thought to be involved in conditions such as Alzheimer`s disease and bipolar disorder. MEM 1003 regulates calcium abnormalities and therefore has a solid rationale as a novel potential therapeutic for such disorders," said David A. Lowe, Ph.D., Chief Scientific Officer of Memory Pharmaceuticals. "We are delighted to have entered into this partnership with SMRI, which brings together Memory Pharmaceuticals` extensive preclinical and clinical experience with MEM 1003 and SMRI`s knowledge and clinical expertise in bipolar disorder. This partnership will allow us to evaluate the potential of MEM 1003 in bipolar disorder concurrently with our ongoing Phase 2a clinical program in Alzheimer`s disease."

"The Stanley Medical Research Institute collaborates with academic and corporate partners to advance the clinical development of promising treatments for bipolar disorder and schizophrenia," said Michael Knable, Executive Director of SMRI. "MEM 1003 represents a promising approach to the treatment of bipolar disorder, and we are pleased to be working with Memory Pharmaceuticals to take MEM 1003 into a proof-of-concept trial in bipolar disorder."

MEM 1003 is a neuronal L-type calcium channel modulator that Memory Pharmaceuticals is developing for the treatment of Alzheimer`s disease and bipolar disorder. By blocking L-type calcium channels, MEM 1003 may regulate the flow of calcium and reestablish normal levels of calcium, which may correct or prevent the severe mood swings that characterize bipolar disorder.

Separately, Memory Pharmaceuticals announced today top-line data from its Phase 1b safety and tolerability study of MEM 1003 for the treatment of Alzheimer`s disease.

Conference Call and Webcast Information

Memory Pharmaceuticals will hold a conference call today at 9:00 a.m. EST to discuss the SMRI agreement and data from the MEM 1003 Phase 1b safety and tolerability study. The conference call will also be broadcast live from the "Investors" section of the Company`s Web site.

Jim Sulat, President and Chief Executive Officer, and Dr. David Lowe, Chief Scientific Officer, will host the conference call.


Investors and other interested parties may access the call as follows:

Date: Tuesday, December 20, 2005
Time: 9:00 a.m. EST
Telephone (U.S.): 800-638-5495
Telephone (international): 617-614-3946
Participant Passcode: 10758595
Webcast: http://www.memorypharma.com under the
"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EST on Tuesday, December 20, 2005, until Tuesday, December 27, 2005. To access the replay, please dial 888-286-8010 (U.S.) or 617-801-6888 (international) and enter passcode number 31705394. An audio replay of the conference call will also be available under the "Investors" section of the Company`s Web site during the same period.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer`s disease, schizophrenia, depression, bipolar disorder, vascular dementia, mild cognitive impairment, Parkinson`s disease and memory impairments associated with aging. For additional information, please visit our Web site at http://www.memorypharma.com .

About the Stanley Medical Research Institute

The Stanley Medical Research Institute is the largest private source of research funding for severe mental illness. SMRI supports research in academic and corporate environments that is directly linked to discovering new treatments for bipolar disorder and schizophrenia. Further information about SMRI can be obtained at http://www.stanleyresearch.org .

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management`s expectations, beliefs, goals, plans or Memory Pharmaceuticals` prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the risks and uncertainties associated with: Memory Pharmaceuticals` ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals` dependence on its collaborations and its license relationship with Bayer; conducting preclinical and clinical trials of Memory Pharmaceuticals` drug candidates that demonstrate these candidates` safety and effectiveness; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals` drug candidates; achieving milestones under Memory Pharmaceuticals` collaborations; obtaining additional financing to support Memory Pharmaceuticals` R&D and clinical activities and operations; Memory Pharmaceuticals` dependence on third-party preclinical or clinical research organizations, manufacturers and consultants; and protecting the intellectual property developed by or licensed to Memory Pharmaceuticals. These and other risks are described in greater detail in Memory Pharmaceuticals` filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.




--------------------------------------------------------------------------------
Source: Memory Pharmaceuticals Corp.

[kobv]

MEMY charttechnisch ausgebrochen, niedrige Marktkapitalisierung!!!
Grüße
kobv